Clinical trials: Vaccination
COVID-19 Vaccination
Developing and Testing a COVID-19 Vaccination Acceptance Intervention
The COVID-19 pandemic has resulted in significant loss of life and suffering with total case and death counts increasing daily, particularly with the emergence of the delta variant.
- Trial name
- CoVAcS (NCT05027464)
- Testing
- Moving to COVID-19 Vaccine Acceptance Intervention
- Where
- 2 sites in United States
- Volunteers
- 338,718 people
- Sponsor
- VA Office of Research and Development
Immunosuppression
Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression
Biomedical Lay Summary Title: Characterization of immune response to vaccination in patients receiving single-drug immunosuppressive therapy Principal Investigator: Robert Swerlick, MD Other Investigators: Rafi Ahmed, PhD Suephy…
- Trial name
- NCT01733056
- Testing
- Flu Vaccine
- Where
- 2 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Emory University
Efficacy of the New CPRV
Immune Response in Adults to PrEP and Simulated Booster PEP With a New CPRV
Pre exposure rabies vaccination with a new Chromatographically Purified Vero-cell Rabies Vaccine(SPEEDA) is as effective as Purified Vero-cell Rabies vaccine.
- Trial name
- NCT01603875
- Testing
- New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).
- Where
- Thailand
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Queen Saovabha Memorial Institute
Hepatitis B
Safety and Immunogenicity of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine
In this study, subjects who received primary neonatal vaccination with hepatitis B vaccine at 0, 1, 2, 12 months, 20 years ago in the 103860/272 primary study will be evaluated for immunological memory to hepatitis B vaccine via…
- Trial name
- NCT00657657
- Testing
- Engerix™-B
- Where
- Thailand
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)
The purpose of this study is to determine if a Vero cell-derived trivalent seasonal influenza vaccine produced by the modified manufacturing process: 1.
- Trial name
- NCT01773928
- Testing
- Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified), VCIV manufactured with the current manufacturing process (VCIV current), Fluzone®, licensed trivalent influenza vaccine (TIV)
- Where
- 20 sites in United States
- Volunteers
- 1,928 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Japanese Encephalitis
Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51
The study investigates a rapid immunization regime of the Japanese Encephalitis vaccine IC51 (JE-PIV) in healthy subjects aged > or = 18 years
- Trial name
- NCT00595790
- Testing
- IC51
- Volunteers
- 374 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Smallpox
Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults
The objective of this study is to determine the minimum dose of ACAM2000 needed to produce a cutaneous reaction in at least 90% of a population of healthy adults at least 28 years of age and previously vaccinated against smallpox.
- Trial name
- NCT00053482
- Testing
- ACAM2000 Smallpox Vaccine, Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®
- Where
- 3 sites in United States
- Volunteers
- 357 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
High-Risk Melanoma
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma
This study will evaluate the immunization effects of a vaccine for patients who are at risk for recurrence of their skin cancer. That is, the risk of cancer is higher if melanoma has invaded deep into the skin or lymph nodes.
- Trial name
- NCT00273910
- Testing
- gp100:209-217 (210M), Montanide ISA-51, Imiquimod
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- National Cancer Institute (NCI)
Arthritis, Rheumatoid
MTX Discontinuation and Vaccine Response
To investigate whether a short term discontinuation of methotrexate (MTX) will improve the vaccination efficacy to seasonal influenza vaccination without deteriorating RA disease activity in a randomized clinical trial.
- Trial name
- NCT02748785
- Testing
- Methotrexate, Seasonal Influenza vaccine
- Where
- South Korea
- Volunteers
- 277 people
- Sponsor
- Seoul National University Hospital
End Stage Kidney Disease
Phenotyping Seroconversion Following Vaccination Against COVID-19 in Patients on Haemodialysis Study
Patients on haemodialysis are at higher risk of getting a severe form of COVID-19 if they become infected. Vaccinations are soon to arrive and offer great hope of controlling the current pandemic.
- Trial name
- NCT04815850
- Where
- United Kingdom
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Infections, Meningococcal
Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination
The purpose of this study is to evaluate the immunogenicity, reactogenicity and safety of a booster dose of GSK Biologicals' MenACWY-TT vaccine administered at 6 years post-primary vaccination with either GSK Biologicals'…
- Trial name
- NCT01777308
- Testing
- Meningococcal conjugate vaccine GSK134612
- Where
- 8 sites in Australia
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Pertussis
Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B
The aim of this study was to evaluate the immunogenicity and safety of the Quinvaxem vaccine (a liquid combination vaccine against diphtheria, tetanus, B. pertussis, hepatitis B and H. influenzae Type B).
- Conditions
- Diphtheria, Pertussis, Tetanus, Hepatitis B
- Trial name
- NCT01362517
- Testing
- Quinvaxem
- Where
- Vietnam
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Neoplasms, Rectal
A Post-marketing Surveillance Study to Assess the Safety of Cervarix (GlaxoSmithKline [GSK] Biologicals' Human Papillomavirus [HPV] -16/18 Vaccine), When Administered According to the Approved Prescribing Information (PI) in Korea
The purpose of this post-marketing surveillance (PMS) study is to collect safety information on the use of Cervarix upon the expanded indication to anal cancer to both women and men (at least 600 Korean women and men) within 30…
- Trial name
- NCT03671369
- Testing
- Safety data collection (following routine vaccination) by a continuous surveillance method.
- Where
- 29 sites in South Korea
- Volunteers
- 670 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Respiratory Tract Infections
Patient Portal Flu Vaccine Reminders (5)
This trial is taking place in Los Angeles, CA at clinics within the UCLA Health System. The study design is a 2x2 nested factorial design.
- Trial name
- NCT05525494
- Testing
- Text Fixed R/R Messages with Direct Appointment Schedule Link, Text Pre-Appointment Reminder, Portal Pre-Commitment Prompt with Tailored R/R Messages with Direct Appointment Schedule Link
- Where
- United States
- Volunteers
- 262,085 people
- Sponsor
- University of California, Los Angeles
Melanoma
Immunotherapy of Stage III/IV Melanoma Patients
The purpose of this study is to determine whether vaccination with melanoma antigen peptides [Melan-A/Mart-1 (both EAA and ELA), NY-ESO-1b analog, Long NY-ESO-1 LP and MAGE-A10] and Montanide, CpG adjuvants and low dose rIL-2 can…
- Trial name
- NCT00112242
- Testing
- Melan-A ELA + Montanide, Melan-A ELA + NY-ESO-1b + MAGE-A10 + Montanide, Melan-A -ELA + NY-ESO-1b + MAGE-A10 peptide + Montanide + CpG
- Where
- 2 sites in Switzerland
- Volunteers
- 39 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Malaria
Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
This first-in-human clinical trial, was a dose escalation multi-center trial designed to assess the safety, tolerability, and immunogenicity of the vaccine component, BNT165b1, a ribonucleic acid (RNA)-lipid nanoparticle (LNP)…
- Trial name
- NCT05581641
- Testing
- BNT165b1
- Where
- 5 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Gastroenteritis, Rotavirus
Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)
To observe the safety, tolerability and immunogenicity of the administration of 3 doses of rotateq in healthy Indian infants between 6 weeks through exactly 12 weeks of age at entry.
- Trial name
- NCT00496054
- Testing
- Rotavirus Vaccine, Live, Oral, Pentavalent
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Meningococcal
Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration
The purpose of this study is to demonstrate, in 12-23 months old subjects, the non-inferiority of meningococcal vaccine GSK134612 and pneumococcal vaccine GSK1024850A when co-administered, compared to each vaccine administered…
- Trial name
- NCT00758264
- Testing
- Meningococcal vaccine GSK134612, Pneumococcal vaccine GSK1024850A
- Where
- 5 sites in Mexico, Taiwan
- Volunteers
- 363 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Health Care Utilization, Vaccine Preventable Disease
Effect of Varied Outreach Methods on Appointment Scheduling, Appointment Completion, and Receipt of COVID-19 Vaccination
Our objective is to determine the effectiveness of varied outreach methods to children age 12-17 years old who are due for a well child check visit and don't have one scheduled in the next 45 days on the outcomes of appointment…
- Trial name
- NCT04904744
- Testing
- Low tailored message, No message, Low tailored message plus COVID-19 vaccine message
- Where
- United States
- Volunteers
- 1,235 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Rubella, Mumps
Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age
The purpose of this study is to compare two measles, mumps and rubella conjugate vaccines (manufactured by GSK and Merck and Company ) in terms of the immune response elicited and safety with a six month follow-up after first…
- Conditions
- Rubella, Mumps, Measles, Measles-Mumps-Rubella Vaccine
- Trial name
- NCT00861744
- Testing
- GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), Varivax®
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 1,259 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline